Reports Q1 2025 Results with Net Revenues and Gross Profit Increases of 15.9% Respectively, as Compared to Q1 2024
Conference Call Scheduled for Friday, May 16, at 9:00 a.m. Eastern Time (Friday, May 16, at 9:00 p.m. Beijing Time) with Accompanying Audio and Slide Webcast
Read MoreAs credit card identity theft becomes the most reported type of fraud in the United States, New York residents are among the most affected. With thousands of new accounts opened fraudulently, Petroff Amshen LLP steps in to help victims take legal action and restore their credit. The firm emphasizes the importance of going beyond credit monitoring to reclaim financial control.
Read MoreFirst quarter 2025 gross margin, excluding FaZe Media of 22.8%
Significant year-over-year improvement in first quarter 2025 adjusted EBITDA
Completed remaining divestiture of FaZe Media on April 1, 2025, which is expected to expand gross margin and eliminate approximately $2.5 million in quarterly cash burn going forward
Improved first quarter profitability in line with expectations and supports GameSquare's strategic focus on achieving positive cash flow and adjusted EBITDA in 2025
Read MoreThe combined net Q1 2025 revenue of approximately $2.2 million for prescription and non-prescription products, including license revenue, decreased approximately 6% versus net Q1 2024 revenue of $2.4 million and 37% versus net Q4 2024 revenue of $3.5 million
Mytesi prescription volume increased by approximately 1.8% in Q1 2025 over Q1 2024 and decreased by approximately 13.5% in Q1 2025 over Q4 2024
REMINDER: Today Jaguar to host investor webcast at 4:15 p.m. Eastern regarding Q1 2025 financials and company updates; Click here to register
Proof-of-concept (POC) results show crofelemer reduced total parenteral nutrition in patients with rare orphan diseases microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF) by up to 27% and 12.5% - potential to modify disease progression in intestinal failure patients; Click here to access replay of April 30, 2025 investor webcast about results; additional POC results expected throughout 2025 for MVID and SBS-IF
FDA meeting in Q2 2025 on statistically significant results of Phase 3 OnTarget trial of crofelemer in prespecified subgroup of patients with breast cancer
Read More
Transaction Highlights:
Secured aggregate gross proceeds of up to $50 million from leading institutional investors, consisting of $50 million senior secured convertible note due 2028 to be provided in two tranches of $15 million and $35 million.
New capital to drive growth in Europe and North America, supporting long-term revenue-generating infrastructure
Expansion into full-service provider model, enabling multi-revenue streams including ultra-fast charging, energy trading, and advertising
Exclusive projects secured at over 300 locations across Germany, with international rollout underway
Company expects significant recurring revenue starting late 2025 into 2026
The transaction was fully subscribed, and the subscription period has concluded. The offering closed on May 2, 2025.
Strategic Partnership Accelerates Digital Transformation for Credit Unions of All Sizes, Enhancing Member Experience Through Scalable, Next-Generation Banking Solutions
Read MoreDiamonds & Pearls: Where love meets affordable luxury & couture - A curated, tech-driven boutique that redefines how the modern bride discovers, shops, and celebrates finding their dream dress
Read More
As injuries sideline star players during National Basketball Association playoffs, the inventors of sustained acoustic medicine will present the FDA-cleared sam® device for soft tissue healing at the NBATA Sports Medicine Meeting in Chicago and the CATS Conference in Las Vegas.
Read More
